What is Chardan Capital Markets's price target for OTLK?

Chardan Capital Markets's latest stated price target for Outlook Therapeutics Inc. (OTLK) is $3, from its action on Feb 15, 2024.

What is Chardan Capital Markets's rating on OTLK?

Chardan Capital Markets rates OTLK Neutral, a neutral rating, as of Dec 2, 2024.

When did Chardan Capital Markets last change its view on OTLK?

On Dec 2, 2024, Chardan Capital Markets downgrades to Neutral from Buy.

Analyst firms · Chardan Capital Markets · OTLK

Chardan Capital Markets OTLK price target and rating history

Outlook Therapeutics Inc. (OTLK) · Health Care

Chardan Capital Markets rates Outlook Therapeutics Inc. (OTLK) Neutral with a $3 price target, as of its latest action on Dec 2, 2024. It has published 4 rating actions on OTLK since September 2022, including 1 upgrade and 2 downgrades.

Current rating: Neutral
Price target: $3
Median target, all firms: Too few
Actions on OTLK: 4

Chardan Capital Markets price target on OTLK

Chardan Capital Markets price target on OTLK, each point a stated target, September 2022 to February 2024.

Every Chardan Capital Markets rating on OTLK

Dec 2, 2024
DowngradeChardan Capital Markets downgrades to Neutral from Buy
Feb 15, 2024
UpgradeChardan Capital Markets upgrades to Buy from Neutral, price target $3
Aug 31, 2023
DowngradeChardan Capital Markets downgrades to Neutral from Buy
Sep 13, 2022
InitiateChardan Capital Markets starts coverage at Buy, price target $10

Questions about Chardan Capital Markets and OTLK

What is Chardan Capital Markets's price target for OTLK?: Chardan Capital Markets's latest stated price target for Outlook Therapeutics Inc. (OTLK) is $3, from its action on Feb 15, 2024.
What is Chardan Capital Markets's rating on OTLK?: Chardan Capital Markets rates OTLK Neutral, a neutral rating, as of Dec 2, 2024.
When did Chardan Capital Markets last change its view on OTLK?: On Dec 2, 2024, Chardan Capital Markets downgrades to Neutral from Buy.

More OTLK rating histories

All Chardan Capital Markets ratings OTLK news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.